Samjin new anti-AIDS compound attracting academic interests.

Published: 2006-05-18 06:56:00

Updated: 2006-05-18 06:56:00

Samjin Pharm. announced on May 15 that the company made a technical licensing out agreement for a new drug of AIDS therapy with ImQuest, an American new drug R&D company.

ImQuest delivered a presentation on the subject of Samjin's new AIDS drug during the 19th ICAR conference at Puerto Rico f...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK